A Phase 4 interventional study of Boostrix® and Menactra™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 24 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-17.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.
Among the 22 studies testing boostrix in Tetanus, this one is the 4th largest by enrollment, is one of 4 that started in 2006, is one of 8 in phase 4, and was the 1st registered.
318 studies on the registry are indexed under Tetanus; 29 are open to participants now.
Browse Tetanus studies →2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2006.
This study's enrollment of 1,344 is above the median of 418 across 280 interventional studies indexed under Tetanus.
Median enrollment 554 across the 22 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 8th largest by enrollment of the 98 interventional ones that give a count, is one of 15 that started in 2006, is one of 22 in phase 4, and was the 12th registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing boostrix in Tetanus, from their registry updates:
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
New immunization recommendations in the US include vaccination of adolescents against pertussis and meningococcal disease. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed) and MCV4 (Meningococcal conjugate vaccine against serotypes A, C, Y and W-135) vaccines be administered to adolescents at the same office visit if vaccination with both vaccines is indicated. Therefore, this study is designed to evaluate the safety and immunogenicity of a booster vaccination with Boostrix co-administered with Menactra as compared to the administration of either vaccine alone in healthy adolescents 11 - 18 years of age.
A phase IV, randomized, partially blinded multicenter study to evaluate the safety and immunogenicity of a booster vaccination with GlaxoSmithKline's tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed [Tdap Boostrix®] co-administered intramuscularly with Aventis-Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra™) as compared to the administration of either vaccine alone in healthy adolescents 11-18 years of age. "Experimental design: Prospective, randomized, controlled multicenter study with three groups:
Group 1: Boostrix + Menactra on Day 0, blood samples at Month 0 and Month 1 Group 2: Boostrix on Day 0, Menactra at Month 1, blood samples at Month 0, Month 1, and Month 2 Group 3: Menactra on Day 0, Boostrix at Month 1, blood samples at Month 0, Month 1 and Month 2 Treatment allocation: randomized 1:1:1 Type of study: self-contained Duration of the study: Approximately one month for each subject in Group 1 and approximately two months for each subject in the Group 2 and Group 3."
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
Biological: Boostrix® · Biological: Menactra™
Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
Biological: Boostrix® · Biological: Menactra™
Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
Biological: Boostrix® · Biological: Menactra™
GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
Time frame: At Month 1 (post Boostrix vaccination)
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Month 1 (post Boostrix vaccination)
Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
Time frame: At Month 1 (post Boostrix vaccination)
Number of Subjects With Vaccine Responses for Serum Bactericidal Assay Against Neisseria Meningitidis Serogroups A (rSBA-MenA), C (rSBA-MenC), Y (rSBA-MenY) and W-135 (rSBA-MenW-135)
Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra vaccination; and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with Menactra vaccine.
Time frame: One month post Boostrix vaccination ((Month 1 for Boostrix + Menactra Group and Month 2 for Menactra-Boostrix Group)
Number of Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
Time frame: At Day 0 (PRE) before Boostrix vaccination
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
Time frame: At Month 2 (one month post Boostrix vaccination)
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens
Cut-off values assessed were greater than or equal to 0.1 international units per milliliter (IU/m L).
Time frame: PRE (Day 0) and POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Number of Subjects With Booster Responses for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 0.1 IU/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 0.4 IU/mL), one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
Time frame: At one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
Time frame: PRE (Day 0) and one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
Time frame: At one month POST Menactra vaccination (Month 2 for Boostrix-Menactra Group and Month 1 for Menactra-Boostrix Group)
Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
Time frame: At Month 2 (one month post Boostrix vaccination)
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
Time frame: At Day 0 before (PRE) Boostrix vaccination
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
Time frame: At Month 2 (one month post Boostrix vaccination)
Titers for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies
Antibody titers are presented as geometric mean titers (GMTs).
Time frame: PRE (Day 0) and one month POST Menactra vaccination (Month 2 for Boostrix + Menactra Group and Boostrix-Menactra Group / Month 1 for Menactra-Boostrix Group)
Number of Subjects With Vaccine Responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies
Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra the vaccine, and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with the Menactra vaccine.
Time frame: At Month 2 (one month after vaccination with Menactra vaccine)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = any solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activities. Grade 3 redness/swelling = redness/swelling with diameter ≥ 50 millimeters (mm).
Time frame: Within 4-days (Day 0-3) after each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\], headache and gastrointestinal symptoms \[gastro sympt\]. Any = any solicited general symptom irrespective of intensity grade or relationship to vaccination. Grade 3 = symptoms that prevented normal activities. Grade 3 Fever = temperature higher than (\>) 39° C. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain.
Time frame: Within 4-days (Days 0-3) after each dose and across doses
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE =An AE which prevented normal, everyday activities. Such an AE, for example, prevented attendance at work/school and necessitated the administration of corrective therapy. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within the 31-day (Days 0-30) period after each vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Throughout the entire study period (Day 0 - Month 2)
| Milestone | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Started | 446 | 446 | 449 |
| Completed | 443 | 429 | 441 |
| Not completed | 3 | 17 | 8 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Serious adverse events | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 6 | 4 |
| Withdrew: Lost to follow-up | 1 | 7 | 2 |
| Withdrew: Other | 0 | 1 | 0 |
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group |
|---|---|---|
| Anti-D | 427 | 405 |
| Anti-T | 425 | 412 |
Concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix + Menactra Group | Boostrix-Menactra Group |
|---|---|---|
| Anti-PT | 63.9 (58.6 to 69.7) | 74.3 (67.9 to 81.3) |
| Anti-FHA | 444.8 (415.0 to 476.7) | 575.8 (532.8 to 622.1) |
| Anti-PRN | 253.4 (224.8 to 285.6) | 366.0 (321.6 to 416.6) |
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group |
|---|---|---|
| Anti-PT, Total | 322 | 333 |
| Anti-FHA, Total | 385 | 388 |
| Anti-PRN, Total | 398 | 394 |
Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra vaccination; and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with Menactra vaccine.
| Participants | Boostrix + Menactra Group | Menactra-Boostrix Group |
|---|---|---|
| rSBA-MenA, Total | 329 | 328 |
| rSBA-MenC, Total | 390 | 383 |
| rSBA-MenY, Total | 369 | 358 |
| rSBA-MenW-135, Total | 404 | 394 |
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| ANTI-D, PRE | 109 | 93 | 120 |
| ANTI-T, PRE | 201 | 181 | 195 |
Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
| Participants | Menactra-Boostrix Group |
|---|---|
| Anti-D | 428 |
| Anti-T | 426 |
Cut-off values assessed were greater than or equal to 0.1 international units per milliliter (IU/m L).
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Anti-D, PRE | 399 | 383 | 391 |
| Anti-T, PRE | 423 | 409 | 423 |
| ANTI-D, POST | 428 | 415 | 429 |
| ANTI-T, POST | 428 | 415 | 429 |
Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 0.1 IU/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 0.4 IU/mL), one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Anti-D, Total | 422 | 377 | 422 |
| Anti-T, Total | 310 | 330 | 329 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
| IU/mL | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Anti-D, PRE | 0.5 (0.4 to 0.6) | 0.5 (0.4 to 0.5) | 0.5 (0.4 to 0.5) |
| Anti-D, POST | 40.1 (36.9 to 43.5) | 10.2 (9.3 to 11.2) | 27.3 (25.1 to 29.6) |
| Anti-T, PRE | 1.0 (0.9 to 1.1) | 0.8 (0.8 to 0.9) | 0.9 (0.8 to 1.0) |
| Anti-T, POST | 9.5 (8.9 to 10.2) | 12.7 (11.8 to 13.8) | 12.2 (11.3 to 13.2) |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
| IU/mL | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|
| Anti-D | 16.5 (15.4 to 17.6) | 41.6 (38.1 to 45.5) |
| Anti-T | 10.0 (9.2 to 10.8) | 0.9 (0.8 to 1.0) |
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.
| Participants | Menactra-Boostrix Group |
|---|---|
| Anti-PT, Total | 338 |
| Anti-FHA, Total | 405 |
| Anti-PRN, Total | 414 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Anti-PT | 8.6 (7.7 to 9.6) | 10.0 (8.9 to 11.3) | 10.3 (9.2 to 11.6) |
| Anti-FHA | 46.5 (41.4 to 52.3) | 43.8 (39.1 to 49.0) | 47.8 (42.4 to 53.8) |
| Anti-PRN | 12.5 (11.1 to 14.1) | 10.6 (9.3 to 12.0) | 12.0 (10.6 to 13.5) |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
| EL.U/mL | Menactra-Boostrix Group |
|---|---|
| Anti-PT | 77.8 (71.5 to 84.6) |
| ANTI-FHA | 653.0 (603.6 to 706.5) |
| Anti-PRN | 412.5 (364.5 to 466.9) |
Antibody titers are presented as geometric mean titers (GMTs).
| Titers | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| rSBA-MenA, PRE | 533.4 (464.6 to 612.3) | 490.8 (428.4 to 562.3) | 449.4 (383.4 to 526.6) |
| rSBA-MenA, POST | 10406.1 (9687.2 to 11178.3) | 7220.0 (6613.3 to 7882.4) | 9466.3 (8765.6 to 10222.9) |
| rSBA-MenC, PRE | 21.0 (17.2 to 25.5) | 16.4 (13.6 to 19.8) | 18.7 (15.3 to 22.8) |
| rSBA-MenC, POST | 2760.2 (2387.5 to 3191.1) | 1137.0 (969.6 to 1333.3) | 2702.8 (2292.6 to 3186.5) |
| rSBA-MenY, PRE | 53.8 (43.6 to 66.5) | 51.4 (41.6 to 63.5) | 56.2 (45.1 to 70.1) |
| rSBA-MenY, POST | 3244.2 (2884.1 to 3649.1) | 1470.7 (1311.4 to 1649.3) | 3022.8 (2687.0 to 3400.6) |
| rSBA-MenW-135, PRE | 23.7 (19.5 to 28.6) | 28.0 (23.1 to 34.0) | 32.2 (26.6 to 39.0) |
| rSBA-MenW-135, POST | 4822.1 (4351.6 to 5343.4) | 2143.1 (1913.9 to 2399.8) | 4154.3 (3690.9 to 4675.9) |
Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra the vaccine, and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with the Menactra vaccine.
| Participants | Boostrix-Menactra Group |
|---|---|
| rSBA-MenA, Total | 300 |
| rSBA-MenC, Total | 351 |
| rSBA-MenY, Total | 325 |
| rSBA-MenW-135, Total | 360 |
Assessed solicited local symptoms were pain, redness and swelling. Any = any solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activities. Grade 3 redness/swelling = redness/swelling with diameter ≥ 50 millimeters (mm).
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Pain, Any, Dose 1 | 331 | 304 | 236 |
| Pain, Grade 3, Dose 1 | 26 | 14 | 6 |
| Redness, Any, Dose 1 | 118 | 111 | 84 |
| Redness, ≥ 50 mm, Dose 1 | 10 | 1 | 4 |
| Swelling, Any, Dose 1 | 99 | 78 | 56 |
| Swelling, ≥ 50 mm, Dose 1 | 8 | 7 | 5 |
| Pain, Any, Dose 2 | NA | 260 | 211 |
| Pain, Grade 3, Dose 2 | NA | 13 | 4 |
| Redness, Any, Dose 2 | NA | 85 | 79 |
| Redness, ≥ 50 mm, Dose 2 | NA | 8 | 2 |
| Swelling, Any, Dose 2 | NA | 64 | 53 |
| Swelling, ≥ 50 mm, Dose 2 | NA | 9 | 3 |
| Pain, Any, Across doses | 331 | 343 | 291 |
| Pain, Grade 3, Across doses | 26 | 26 | 9 |
| Redness, Any, Across doses | 118 | 141 | 119 |
| Redness, ≥ 50 mm, Across doses | 10 | 8 | 6 |
| Swelling, Any, Across doses | 99 | 105 | 84 |
| Swelling, ≥ 50 mm, Across doses | 8 | 13 | 8 |
Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\], headache and gastrointestinal symptoms \[gastro sympt\]. Any = any solicited general symptom irrespective of intensity grade or relationship to vaccination. Grade 3 = symptoms that prevented normal activities. Grade 3 Fever = temperature higher than (\>) 39° C. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain.
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Fatigue, Any, Dose 1 | 150 | 139 | 114 |
| Fatigue, Grade 3, Dose 1 | 13 | 9 | 5 |
| Fatigue, Related, Dose 1 | 120 | 113 | 86 |
| Fever (orally), Any, Dose 1 | 23 | 15 | 21 |
| Fever (orally), Grade 3, Dose 1 | 2 | 1 | 0 |
| Fever (orally), Related, Dose 1 | 20 | 8 | 16 |
| Gastro sympt., Any, Dose 1 | 67 | 63 | 60 |
| Gastro sympt, Grade 3, Dose 1 | 4 | 4 | 2 |
| Gastro sympt, Related, Dose 1 | 46 | 41 | 36 |
| Headache, Any, Dose 1 | 150 | 133 | 116 |
| Headache, Grade 3, Dose 1 | 12 | 12 | 7 |
| Headache, Related, Dose 1 | 127 | 104 | 85 |
| Fatigue, Any, Dose 2 | NA | 103 | 90 |
| Fatigue, Grade 3, Dose 2 | NA | 5 | 3 |
| Fatigue, Related, Dose 2 | NA | 83 | 70 |
| Fever (orally), Any, Dose 2 | NA | 14 | 10 |
| Fever (orally), Grade 3, Dose 2 | NA | 1 | 1 |
| Fever (orally), Related, Dose 2 | NA | 9 | 9 |
| Gastro sympt., Any, Dose 2 | NA | 46 | 34 |
| Gastro sympt., Grade 3, Dose 2 | NA | 1 | 3 |
| Gastro sympt., Related, Dose 2 | NA | 32 | 24 |
| Headache, Any, Dose 2 | NA | 95 | 75 |
| Headache, Grade 3, Dose 2 | NA | 2 | 2 |
| Headache, Related, Dose 2 | NA | 72 | 56 |
| Fatigue, Any, Across | 150 | 175 | 160 |
| Fatigue, Grade 3, Across | 13 | 13 | 7 |
| Fatigue, Related, Across | 120 | 146 | 128 |
| Fever (orally), Any, Across | 23 | 28 | 29 |
| Fever (orally), Grade 3, Across | 2 | 2 | 1 |
| Fever (orally), Related, Across | 20 | 16 | 23 |
| Gastro sympt., Any, Across | 67 | 96 | 80 |
| Gastro sympt., Grade 3, Across | 4 | 5 | 5 |
| Gastro sympt., Related, Across | 46 | 65 | 54 |
| Headache, Any, Across | 150 | 177 | 157 |
| Headache, Grade 3, Across | 12 | 13 | 9 |
| Headache, Related, Across | 127 | 142 | 121 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE =An AE which prevented normal, everyday activities. Such an AE, for example, prevented attendance at work/school and necessitated the administration of corrective therapy. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Any AEs | 124 | 149 | 155 |
| Grade 3 AEs | 16 | 15 | 22 |
| Related AEs | 37 | 44 | 29 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 0 | 1 |
Collected over Solicited local and general symptoms during the 4-day (Day 0-3) follow-up period, unsolicited AEs during the 31-day (Day 0-30) follow-up period after each vaccination and SAEs throughout the study (Day 0 - Month 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix + Menactra Group | — | 1/446 (0.2%) | 371/446 (83.2%) |
| Boostrix-Menactra Group | — | 0/446 (0%) | 385/446 (86.3%) |
| Menactra-Boostrix Group | — | 1/449 (0.2%) | 358/449 (79.7%) |
| Event | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| Extradural hematomaInjury, poisoning and procedural complications | 1/446 | 0/446 | 0/449 |
| Facial bones fractureInjury, poisoning and procedural complications | 1/446 | 0/446 | 0/449 |
| LeukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/446 | 0/446 | 1/449 |
| Event | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group |
|---|---|---|---|
| PainGeneral disorders | 331/446 | 343/446 | 291/449 |
| HeadacheGeneral disorders | 150/446 | 177/446 | 157/449 |
| FatigueGeneral disorders | 150/446 | 175/446 | 160/449 |
| RednessGeneral disorders | 118/446 | 141/446 | 119/449 |
| SwellingGeneral disorders | 99/446 | 105/446 | 84/449 |
| Gastrointestinal symptomsGeneral disorders | 67/446 | 96/446 | 80/449 |
| Fever (orally)General disorders | 23/446 | 28/446 | 29/449 |
| Age, Continuous(Years) | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group | Total |
|---|---|---|---|---|
| Mean | 13.5 ± 2.31 | 13.2 ± 2.07 | 13.4 ± 2.27 | 13.37 ± 2.22 |
| Sex: Female, Male(Participants) | Boostrix + Menactra Group | Boostrix-Menactra Group | Menactra-Boostrix Group | Total |
|---|---|---|---|---|
| Female | 210 | 233 | 223 | 666 |
| Male | 236 | 213 | 226 | 675 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Jan 2006 to primary completion in Aug 2006, 6 months.
Results were first posted in Mar 2017, 10 years 7 months after primary completion.
Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix